DNA 시퀀싱 시장 규모, 점유율 및 동향 분석 리포트 : 제품·서비스별, 기술별, 워크플로우별, 용도별, 최종 용도별, 부문 예측(2025-2033년)

DNA Sequencing Market Summary

The global DNA sequencing market size was estimated at USD 14.88 billion in 2024 and is projected to reach USD 91.88 billion by 2033, growing at a CAGR of 22.66% from 2025 to 2033. The market's steady growth is driven by rising adoption of next generation sequencing technologies, increasing clinical applications in oncology and rare disease diagnostics, and expanding investments in genomics research globally.

Increasing Adoption of DNA Vaccines

The market for DNA sequencing is seeing a sharp increase in demand due to the growing use of DNA vaccines. High-precision sequencing is essential to the design, validation, and optimization of plasmid constructs encoding antigenic proteins in DNA vaccine development. To ensure proper gene insertion, confirm plasmid integrity, and identify potential mutations during the manufacturing process, sequencing is crucial.

Next-generation sequencing (NGS) is crucial for verifying the genetic stability and purity of large-scale DNA vaccine production, which also requires strict quality control and adherence to regulatory compliance. Sequencing-based workflows for preclinical validation, immunogenicity assessment, and safety profiling have become increasingly popular among developers due to the global shift toward faster vaccine development, which pandemic preparedness initiatives have accelerated.

Global DNA Sequencing Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the DNA sequencing market on the basis of product & services, technology, workflow, application, end use, and region.

• Product & Service Outlook (Revenue, USD Million, 2021 - 2033)
• Instruments
• Consumables
• Services
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Sanger Sequencing
• Next-Generation Sequencing
  • Whole Genome Sequencing (WGS)
  • Whole Exome Sequencing (WES)
  • Targeted Sequencing & Resequencing
• Third Generation DNA Sequencing
  • Single-Molecule Real-Time Sequencing (SMRT)
  • Nanopore Sequencing
• Workflow Outlook (Revenue, USD Million, 2021 - 2033)
• Pre-sequencing
• Sequencing
• Data Analysis
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Oncology
• Reproductive Health
• Clinical Investigation
• Agrigenomics & Forensics
• HLA Typing/Immune System Monitoring
• Metagenomics, Epidemiology & Drug Development
• Consumer Genomics
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Academic Research
• Clinical Research
• Hospitals & Clinics
• Pharmaceutical & Biotechnology Companies
• Other Users
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Product & Service Segment
    • 1.1.1.2. Technology Segment
    • 1.1.1.3. Workflow Segment
    • 1.1.1.4. Application
    • 1.1.1.5. End Use
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objective
  • 1.4.1. Objective 1
  • 1.4.2. Objective2
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis:
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
  • 1.9.2. List of Secondary Sources
  • 1.9.3. List of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables and Trends

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Trends and Outlook
• 3.3. Market Derivers
  • 3.3.1. Increasing adoption of DNA vaccines
  • 3.3.2. Declining cost of genome sequencing
• 3.4. Market Restraint Analysis
  • 3.4.1. Regulatory and quality compliance challenges
• 3.5. Business Environment Analysis
  • 3.5.1. PESTEL Analysis
  • 3.5.2. Porter's Five Forces Analysis

Chapter 4. DNA Sequencing Market: Product & Service Estimates & Trend Analysis

• 4.1. Product & Service Segment Dashboard
• 4.2. Global DNA Sequencing Market: Product & Service Movement Analysis
• 4.3. Consumables
  • 4.3.1. Consumables, 2021 - 2033 (USD Million)
• 4.4. Instruments
  • 4.4.1. Instruments, 2021 - 2033 (USD Million)
• 4.5. Services
  • 4.5.1. Services, 2021 - 2033 (USD Million)

Chapter 5. DNA Sequencing Market: Technology Estimates & Trend Analysis

• 5.1. Technology Segment Dashboard
• 5.2. Global DNA Sequencing market: Technology Movement Analysis
• 5.3. Sanger sequencing
  • 5.3.1. Sanger sequencing market estimates and forecasts 2021 to 2033, (USD Million)
• 5.4. Next-generation sequencing (NGS)
  • 5.4.1. Next-generation sequencing (NGS), 2021 - 2033 (USD Million)
  • 5.4.2. Whole genome sequencing (WGS)
    • 5.4.2.1. Whole genome sequencing (WGS), 2021 - 2033 (USD Million)
  • 5.4.3. Whole exome sequencing (WES)
    • 5.4.3.1. Whole exome sequencing (WES), 2021 - 2033 (USD Million)
  • 5.4.4. Targeted sequencing & resequencing
    • 5.4.4.1. Targeted sequencing & resequencing, 2021 - 2033 (USD Million)
• 5.5. Third generation DNA sequencing
  • 5.5.1. Third generation DNA sequencing, 2021 - 2033 (USD Million)
  • 5.5.2. Single-molecule real-time sequencing (SMRT)
    • 5.5.2.1. Single-molecule real-time sequencing (SMRT), 2021 - 2033 (USD Million)
  • 5.5.3. Nanopore sequencing
    • 5.5.3.1. Nanopore sequencing, 2021 - 2033 (USD Million)

Chapter 6. DNA Sequencing Market: Workflow Estimates & Trend Analysis

• 6.1. Workflow Segment Dashboard
• 6.2. Global DNA Sequencing market: Workflow Movement Analysis
• 6.3. Pre-sequencing
  • 6.3.1. Pre-sequencing, 2021 - 2033 (USD Million)
• 6.4. Sequencing
  • 6.4.1. Sequencing, 2021 - 2033 (USD Million)
• 6.5. Data Analysis
  • 6.5.1. Data analysis, 2021 - 2033 (USD Million)

Chapter 7. DNA Sequencing Market: Application Estimates & Trend Analysis

• 7.1. Application Segment Dashboard
• 7.2. Global DNA Sequencing market: Application Movement Analysis
• 7.3. Oncology
  • 7.3.1. Oncology, 2021 - 2033 (USD Million)
• 7.4. Reproductive Health
  • 7.4.1. Reproductive health, 2021 - 2033 (USD Million)
• 7.5. Clinical Investigation
  • 7.5.1. Clinical investigation, 2021 - 2033 (USD Million)
• 7.6. Agrigenomics & Forensics
  • 7.6.1. Agrigenomics & forensics, 2021 - 2033 (USD Million)
• 7.7. HLA Typing/Immune System Monitoring
  • 7.7.1. HLA Typing/Immune System Monitoring, 2021 - 2033 (USD Million)
• 7.8. Metagenomics, Epidemiology, & Drug Development
  • 7.8.1. Metagenomics, epidemiology, & drug, 2021 - 2033 (USD Million)
• 7.9. Consumer Genomics
  • 7.9.1. Consumer genomics, 2021 - 2033 (USD Million)
• 7.10. Others
  • 7.10.1. Others, 2021 - 2033 (USD Million)

Chapter 8. DNA Sequencing Market: End-use Estimates & Trend Analysis

• 8.1. End-use Segment Dashboard
• 8.2. Global DNA Sequencing Market: End-use Movement Analysis
• 8.3. Academic Research
  • 8.3.1. Academic research, 2021 - 2033 (USD Million)
• 8.4. Clinical Research
  • 8.4.1. Clinical research, 2021 - 2033 (USD Million)
• 8.5. Hospitals & Clinics
  • 8.5.1. Hospitals & clinics, 2021 - 2033 (USD Million)
• 8.6. Pharmaceutical & Biotechnology Companies
  • 8.6.1. Pharmaceutical & biotechnology companies, 2021 - 2033 (USD Million)
• 8.7. Others
  • 8.7.1. Others, 2021 - 2033 (USD Million)

Chapter 9. Regional Business Analysis

• 9.1. Global DNA sequencings market Share By Region, 2024 & 2033
• 9.2. North America
  • 9.2.1. North America DNA sequencings market, 2021 - 2033 (USD Million)
  • 9.2.2. U.S.
    • 9.2.2.1. Key Country Dynamics
    • 9.2.2.2. Competitive Scenario
    • 9.2.2.3. Regulatory Framework
    • 9.2.2.4. U.S. DNA sequencings market, 2021 - 2033 (USD Million)
  • 9.2.3. Canada
    • 9.2.3.1. Key Country Dynamics
    • 9.2.3.2. Competitive Scenario
    • 9.2.3.3. Regulatory Framework
    • 9.2.3.4. Canada DNA sequencings market, 2021 - 2033 (USD Million)
  • 9.2.4. Mexico
    • 9.2.4.1. Key Country Dynamics
    • 9.2.4.2. Competitive Scenario
    • 9.2.4.3. Regulatory Framework
    • 9.2.4.4. Mexico DNA sequencings market, 2021 - 2033 (USD Million)
• 9.3. Europe
  • 9.3.1. Europe DNA sequencings market, 2021 - 2033 (USD Million)
  • 9.3.2. Germany
    • 9.3.2.1. Key Country Dynamics
    • 9.3.2.2. Competitive Scenario
    • 9.3.2.3. Regulatory Framework
    • 9.3.2.4. Germany DNA sequencings market, 2021 - 2033 (USD Million)
  • 9.3.3. UK
    • 9.3.3.1. Key Country Dynamics
    • 9.3.3.2. Competitive Scenario
    • 9.3.3.3. Regulatory Framework
    • 9.3.3.4. UK DNA sequencings market, 2021 - 2033 (USD Million)
  • 9.3.4. France
    • 9.3.4.1. Key Country Dynamics
    • 9.3.4.2. Competitive Scenario
    • 9.3.4.3. Regulatory Framework
    • 9.3.4.4. France DNA sequencings market, 2021 - 2033 (USD Million)
  • 9.3.5. Italy
    • 9.3.5.1. Key Country Dynamics
    • 9.3.5.2. Competitive Scenario
    • 9.3.5.3. Regulatory Framework
    • 9.3.5.4. Italy DNA sequencings market, 2021 - 2033 (USD Million)
  • 9.3.6. Spain
    • 9.3.6.1. Key Country Dynamics
    • 9.3.6.2. Competitive Scenario
    • 9.3.6.3. Regulatory Framework
    • 9.3.6.4. Spain DNA sequencings market, 2021 - 2033 (USD Million)
  • 9.3.7. Denmark
    • 9.3.7.1. Key Country Dynamics
    • 9.3.7.2. Competitive Scenario
    • 9.3.7.3. Regulatory Framework
    • 9.3.7.4. Denmark DNA sequencings market, 2021 - 2033 (USD Million)
  • 9.3.8. Sweden
    • 9.3.8.1. Key Country Dynamics
    • 9.3.8.2. Competitive Scenario
    • 9.3.8.3. Regulatory Framework
    • 9.3.8.4. Sweden DNA sequencings market, 2021 - 2033 (USD Million)
  • 9.3.9. Norway
    • 9.3.9.1. Key Country Dynamics
    • 9.3.9.2. Competitive Scenario
    • 9.3.9.3. Regulatory Framework
    • 9.3.9.4. Norway DNA sequencings market, 2021 - 2033 (USD Million)
• 9.4. Asia Pacific
  • 9.4.1. Asia Pacific DNA sequencings market, 2021 - 2033 (USD Million)
  • 9.4.2. Japan
    • 9.4.2.1. Key Country Dynamics
    • 9.4.2.2. Competitive Scenario
    • 9.4.2.3. Regulatory Framework
    • 9.4.2.4. Japan DNA sequencings market, 2021 - 2033 (USD Million)
  • 9.4.3. China
    • 9.4.3.1. Key Country Dynamics
    • 9.4.3.2. Competitive Scenario
    • 9.4.3.3. Regulatory Framework
    • 9.4.3.4. China DNA sequencings market, 2021 - 2033 (USD Million)
  • 9.4.4. India
    • 9.4.4.1. Key Country Dynamics
    • 9.4.4.2. Competitive Scenario
    • 9.4.4.3. Regulatory Framework
    • 9.4.4.4. India DNA sequencings market, 2021 - 2033 (USD Million)
  • 9.4.5. South Korea
    • 9.4.5.1. Key Country Dynamics
    • 9.4.5.2. Competitive Scenario
    • 9.4.5.3. Regulatory Framework
    • 9.4.5.4. South Korea DNA sequencings market, 2021 - 2033 (USD Million)
  • 9.4.6. Australia
    • 9.4.6.1. Key Country Dynamics
    • 9.4.6.2. Competitive Scenario
    • 9.4.6.3. Regulatory Framework
    • 9.4.6.4. Australia DNA sequencings market, 2021 - 2033 (USD Million)
  • 9.4.7. Thailand
    • 9.4.7.1. Key Country Dynamics
    • 9.4.7.2. Competitive Scenario
    • 9.4.7.3. Regulatory Framework
    • 9.4.7.4. Thailand DNA sequencings market, 2021 - 2033 (USD Million)
• 9.5. Latin America
  • 9.5.1. Latin America DNA sequencings market, 2021 - 2033 (USD Million)
  • 9.5.2. Brazil
    • 9.5.2.1. Key Country Dynamics
    • 9.5.2.2. Competitive Scenario
    • 9.5.2.3. Regulatory Framework
    • 9.5.2.4. Brazil DNA sequencings market, 2021 - 2033 (USD Million)
  • 9.5.3. Argentina
    • 9.5.3.1. Key Country Dynamics
    • 9.5.3.2. Competitive Scenario
    • 9.5.3.3. Regulatory Framework
    • 9.5.3.4. Argentina DNA sequencings market, 2021 - 2033 (USD Million)
• 9.6. MEA
  • 9.6.1. MEA DNA sequencings market, 2021 - 2033 (USD Million)
  • 9.6.2. South Africa
    • 9.6.2.1. Key Country Dynamics
    • 9.6.2.2. Competitive Scenario
    • 9.6.2.3. Regulatory Framework
    • 9.6.2.4. South Africa DNA sequencings market, 2021 - 2033 (USD Million)
  • 9.6.3. Saudi Arabia
    • 9.6.3.1. Key Country Dynamics
    • 9.6.3.2. Competitive Scenario
    • 9.6.3.3. Regulatory Framework
    • 9.6.3.4. Saudi Arabia DNA sequencings market, 2021 - 2033 (USD Million)
  • 9.6.4. UAE
    • 9.6.4.1. Key Country Dynamics
    • 9.6.4.2. Competitive Scenario
    • 9.6.4.3. Regulatory Framework
    • 9.6.4.4. UAE DNA sequencings market, 2021 - 2033 (USD Million)
  • 9.6.5. Kuwait
    • 9.6.5.1. Key Country Dynamics
    • 9.6.5.2. Competitive Scenario
    • 9.6.5.3. Regulatory Framework
    • 9.6.5.4. Kuwait DNA sequencings market, 2021 - 2033 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Company Categorization
• 10.2. Strategy Mapping
• 10.3. Company Position Analysis, 2024
• 10.4. Company Profiles/Listing
  • 10.4.1. Thermo Fisher Scientific, Inc
    • 10.4.1.1. Company overview
    • 10.4.1.2. Financial performance
    • 10.4.1.3. Product & service benchmarking
    • 10.4.1.4. Strategic initiatives
  • 10.4.2. Agilent Technology
    • 10.4.2.1. Company overview
    • 10.4.2.2. Financial performance
    • 10.4.2.3. Product & service benchmarking
    • 10.4.2.4. Strategic initiatives
  • 10.4.3. Illumina, Inc.
    • 10.4.3.1. Company overview
    • 10.4.3.2. Financial performance
    • 10.4.3.3. Product & service benchmarking
    • 10.4.3.4. Strategic initiatives
  • 10.4.4. QIAGEN
    • 10.4.4.1. Company overview
    • 10.4.4.2. Financial performance
    • 10.4.4.3. Product & service benchmarking
    • 10.4.4.4. Strategic initiatives
  • 10.4.5. F. Hoffmann-La Roche Ltd.
    • 10.4.5.1. Company overview
    • 10.4.5.2. Financial performance
    • 10.4.5.3. Product & service benchmarking
    • 10.4.5.4. Strategic initiatives
  • 10.4.6. Macrogen, Inc.
    • 10.4.6.1. Company overview
    • 10.4.6.2. Financial performance
    • 10.4.6.3. Product & service benchmarking
    • 10.4.6.4. Strategic initiatives
  • 10.4.7. PerkinElmer Genomics
    • 10.4.7.1. Company overview
    • 10.4.7.2. Financial performance
    • 10.4.7.3. Product & service benchmarking
    • 10.4.7.4. Strategic initiatives
  • 10.4.8. PacBio
    • 10.4.8.1. Company overview
    • 10.4.8.2. Financial performance
    • 10.4.8.3. Product & service benchmarking
    • 10.4.8.4. Strategic initiatives
  • 10.4.9. BGI
    • 10.4.9.1. Company overview
    • 10.4.9.2. Financial performance
    • 10.4.9.3. Product & service benchmarking
    • 10.4.9.4. Strategic initiatives
  • 10.4.10. Bio-Rad Laboratories, Inc.
    • 10.4.10.1. Company overview
    • 10.4.10.2. Financial performance
    • 10.4.10.3. Product & service benchmarking
    • 10.4.10.4. Strategic initiatives
  • 10.4.11. Myriad Genetics
    • 10.4.11.1. Company overview
    • 10.4.11.2. Financial performance
    • 10.4.11.3. Product & service benchmarking
    • 10.4.11.4. Strategic initiatives
  • 10.4.12. PierianDx
    • 10.4.12.1. Company overview
    • 10.4.12.2. Financial performance
    • 10.4.12.3. Product & service benchmarking
    • 10.4.12.4. Strategic initiatives
  • 10.4.13. Partek Incorporated
    • 10.4.13.1. Company overview
    • 10.4.13.2. Financial performance
    • 10.4.13.3. Product & service benchmarking
    • 10.4.13.4. Strategic initiatives
  • 10.4.14. Eurofins Scientific
    • 10.4.14.1. Company overview
    • 10.4.14.2. Financial performance
    • 10.4.14.3. Product & service benchmarking
    • 10.4.14.4. Strategic initiatives